Table 2 Current oncology products with a pharmacogenomics relationship.
From: Emerging strategies and applications of pharmacogenomics
Therapy | Developer | Date approved | Primary indication | Genetic alteration | References |
|---|---|---|---|---|---|
Herceptin | Genentech | September 1998 | Metastatic breast cancer in tumours overexpressing HER2 protein | Amplification of the Her-2 neu gene | |
Gleevec | Novartis | May 2001 | Chronic myeloid leukaemia | Chromosomal translocation, resulting in fusion of BRC and the oncogene Abl, resulting in activated oncogene | |
Iressa | AstraZeneca | May 2003 | Advanced or metastatic non-small-cell lung cancer | Activating mutations in EGFR |